DOCSLIB.ORG

Program and Abstracts Onal Co Ati Nf Rn E E Re T N N I C E

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Program and Abstracts Onal Co Ati Nf Rn E E Re T N N I C E Hosted by the International Society for Antiviral Research (ISAR) onal Co ati nf rn e e re t n n I c June 11-15, 2018 e t s o ALFÂNDEGA CONGRESS CENTRE 1 n 3 A n ) Porto, Portugal R ti A vi C ra (I l Research Program and Abstracts onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A n ) Table Contents R of ti A vi C ra (I l Research Daily Schedule . 3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 The 2018 Chu Family Foundation Scholarship Awardees . 14 Speaker Biographies . 15 Program Schedule . 23 Posters . 36 Abstracts . 59 Author Index . 150 Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 2 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A n ) Daily Schedule R ti A vi C ra (I l Research MONDAY, JUNE 11, 2018 › Women in Science Roundtable › Satellite Workshop of the EU H2020 Consortium ‘ANTIVIRALS’ › Welcome and Keynote Addresses › Recent Technological Advances Session › Opening Reception TUESDAY, JUNE 12, 2018 › Women in Science Award Lecture › Virus Evolution Session › Emerging Infections Session › Influenza Virus Session › Respiratory Viruses Session › Poster Session 1 WEDNESDAY, JUNE 13, 2018 › Antonín Holý Memorial Award Lecture › Viral Hepatitis Session › Hepatitis and Retroviruses Session › New Member and First Time Attendee Networking (featuring a PechaKucha Competition) › Career Development Panel THURSDAY, JUNE 14, 2018 › Gertrude Elion Memorial Award Lecture › Cytomegalovirus Session › Medicinal Chemistry Session › Annual ISAR Business Meeting › William Prusoff Young Investigator Award Lecture › HIV Treatment and Cure Session › Poster Session 2 › Closing Reception and Banquet FRIDAY, JUNE 15, 2018 › Shotgun Oral Presentations › Emerging Infections and Clinical Evaluation of Antivirals Session › DNA Viruses Session Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 3 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A ) ISAR Organization n R ti A vi C ra (I l Research OFFICERS PRESIDENT José Esté Barcelona, Spain PRESIDENT ELECT PAST PRESIDENT Johan Neyts Robert Buckheit, Jr. Leuven, Belgium Frederick, MD, USA TREASURER SECRETARY Brian Gowen Graciela Andrei Logan, UT, USA Leuven, Belgium BOARD OF DIRECTORS Andrea Brancale Jennifer Moffat Mike Bray Cardiff, UK Syracuse, NY, USA Chevy Chase, MD, USA Roger Ptak Rhonda Cardin Kathie Seley-Radtke Frederick, MD, USA Cincinnati, OH, USA Baltimore, MD, USA CONFERENCE COMMITTEE CO-CHAIRS Robert Buckheit, Jr. and Johan Neyts Graciela Andrei Rhonda Cardin Brian Gowen Masanori Baba José Esté Amy Patick Mike Bray Phil Furman Roger Ptak PROGRAM COMMITTEE CO-CHAIRS Justin Julander and Mark Prichard Timothy Block José Esté Randall Lanier Mike Bray Scott James Chris Meier Leen Delang Amy Krafft Johan Neyts The International Society For Antiviral Research (ISAR) The Society was organized in 1987 as a non-profit scientific organization for the purpose of advancing and disseminating knowledge in all areas of antiviral research . To achieve this objective, the Society organizes an annual meeting . The Society is now in its thirty-first year of existence, and has more than 300 members representing 30 countries . Membership application forms will be available at the Conference Registration desk, or from our website at www.isar-icar.com . Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 4 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A ) Contributors n R ti A vi C Confirmed Sponsors as of May 28, 2018 ra (I l Research PLATINUM Gilead Sciences Foster City, CA, USA GOLD Janssen – Pharmaceutical companies of Johnson & Johnson Beerse, Belgium SILVER AbbVie Emergent BioSolutions Novartis Institutes for North Chicago, IL, USA Gaithersburg, MD, USA BioMedical Research Burroughs Wellcome Fund JCR Pharmaceutical Co. Emeryville, CA, USA Research Triangle Park, NC, USA Ashiya, Japan Southern Research Institute Chimerix Birmingham, AL, USA Durham, NC, USA BRONZE ACS Infectious Diseases Elsevier Sanofi Washington, DC, USA Amsterdam, The Netherlands Paris, France AiCuris Anti-infective Cures Institute for Antiviral Research, Toyama Chemical Co. Wuppertal, Germany Utah State University Tokyo, Japan Logan, UT, USA Viroclinics Biosciences Antiva Biosciences Oxeltis Rotterdam, The Netherlands South San Francisco, CA, USA Montpellier, France ViroVet Center for Drug Design, Quanterix Leuven, Belgium University of Minnesota Lexington, MA, USA XpressBio Minneapolis, MN, USA Riboscience Frederick, MD, USA Sunnyvale, CA, USA ADDITIONAL GRANT FUNDING PROVIDED BY: The EU H2020 ANTIVIRALS Consortium* *The ANTIVIRALS consortium has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 642434. Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 5 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A ) Keynotes Networking n and R ti A vi C ra (I l Research KEYNOTE ADDRESSES Monday, June 11, 2018 Epidemic Arboviral Diseases: Implications for Research and Public Health Infrastructure Annelies Wilder-Smith Umeå University, Sweden and WHO, Geneva 3:45 PM ARCHIVE HALL I Hepatitis C Virus: Problem Solved. And Now? Jean-Michel Pawlotsky University of Paris-Est 4:30 PM ARCHIVE HALL I NETWORKING EVENTS Monday, June 11, 2018 Women in Science Roundtable 12:00 PM – 1:45 PM NOBLE HALL Opening Reception 6:45 PM – 8:00 PM NOBLE HALL Wednesday, June 13, 2018 New Member and First Time Attendee Networking featuring a PechaKucha Competition 12:30 PM – 1:30 PM INFANTE HALL Career Development Panel 1:45 PM – 2:45 PM INFANTE HALL Thursday, June 14, 2018 Closing Reception and Banquet 7:00 PM FERREIRA CELLARS (Advance purchase of banquet ticket required; transportation from select hotels provided) Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 6 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A ) Schedule Glance n at a R ti A vi C ra (I l Research MONDAY, JUNE 11, 2018 TIME EVENT LOCATION 11:00 AM – 6:30 PM Registration ARCHIVE HALL FOYER 12:00 PM – 1:45 PM Women in Science Roundtable NOBLE HALL 2:00 PM – 3:45 PM Satellite Workshop of the EU H2020 Consortium ARCHIVE HALL I ‘ANTIVIRALS’ 3:45 PM – 5:15 PM Welcome and Keynote Addresses ARCHIVE HALL I 5:15 PM – 5:45 PM Coffee Break RIBEIRA 5:45 PM – 6:35 PM Recent Technological Advances Session ARCHIVE HALL I 6:45 PM – 8:00 PM Opening Reception NOBLE HALL Light hors d’oeuvres served TUESDAY, JUNE 12, 2018 TIME EVENT LOCATION 8:00 AM – 5:30 PM Registration ARCHIVE HALL FOYER 8:30 AM – 9:00 AM Women in Science Award Lecture ARCHIVE HALL I 9:00 AM – 10:00 AM Virus Evolution Session ARCHIVE HALL I 10:00 AM – 10:30 AM Coffee Break RIBEIRA 10:30 AM – 12:15 PM Emerging Infections Session ARCHIVE HALL I 12:15 PM – 1:30 PM Lunch NOBLE HALL Available for purchase 1:30 PM – 2:35 PM Influenza Virus Session ARCHIVE HALL I 2:35 PM – 3:15 PM Coffee Break RIBEIRA 3:15 PM – 5:00 PM Respiratory Viruses Session ARCHIVE HALL I 5:00 PM – 7:00 PM Poster Session 1 ARCHIVE HALL II Light hors d’oeuvres served Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 7 Schedule at a Glance WEDNESDAY, JUNE 13, 2018 TIME EVENT LOCATION 8:00 AM – 2:30 PM Registration ARCHIVE HALL FOYER 8:30 AM – 9:00 AM Antonín Holý Memorial Award Lecture ARCHIVE HALL I 9:00 AM – 9:10 AM Antiviral Research: Annual Journal Summary ARCHIVE HALL I 9:10 AM – 10:00 AM Viral Hepatitis Session ARCHIVE HALL I 10:00 AM – 10:30 AM Coffee Break RIBEIRA 10:30 AM – 12:15 PM Hepatitis and Retroviruses Session ARCHIVE HALL I 12:30 PM – 1:30 PM New Member and First Time Attendee Networking INFANTE HALL featuring a PechaKucha Competition Light lunch served 1:45 PM – 2:45 PM Career Development Panel INFANTE HALL Snacks and beverages served THURSDAY, JUNE 14, 2018 TIME EVENT LOCATION 8:00 AM – 5:00 PM Registration ARCHIVE HALL FOYER 8:15 AM – 9:00 AM Gertrude Elion Memorial Award Lecture ARCHIVE HALL I 9:00 AM – 10:30 AM Cytomegalovirus Session ARCHIVE HALL I 10:30 AM – 11:00 AM Coffee Break RIBEIRA 11:00 AM – 12:15 PM Medicinal Chemistry Session ARCHIVE HALL I 12:15 PM – 12:30 PM Annual ISAR Business Meeting ARCHIVE HALL I 12:30 PM – 1:30 PM Lunch NOBLE HALL Available for purchase 1:30 PM – 2:00 PM William Prusoff Young Investigator Award Lecture ARCHIVE HALL I 2:00 PM – 3:45 PM HIV Treatment and Cure Session ARCHIVE HALL I 3:45 PM – 5:45 PM Poster Session 2 ARCHIVE HALL II Light hors d’oeuvres served 7:00 PM – 10:30 PM Closing Reception & Banquet FERREIRA CELLARS *Advance purchase of banquet ticket required Transportation provided from select hotels Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 8 Schedule at a Glance FRIDAY, JUNE 15, 2018 TIME EVENT LOCATION 8:00 AM – 12:00 PM Registration ARCHIVE HALL FOYER 8:30 AM – 9:00 AM Shotgun Oral Presentations ARCHIVE HALL I 9:00 AM – 10:30 AM Emerging Infections and Clinical Evaluation ARCHIVE HALL I of Antivirals Session 10:30 AM – 11:00 AM Coffee Break RIBEIRA 11:00 AM – 12:30 PM DNA Viruses and Emerging Viruses Session ARCHIVE HALL I 12:30 PM Conference Concludes Program and Abstracts of the 31st International Conference on Antiviral Research (ICAR) 9 onal Co ati nf rn e e re t n n I c e t s o 1 n 3 A ) 2018 ISAR Award Winners n R ti A vi C ra (I l Research Gertrude Elion Memorial Lecture Awardee Paul Griffiths, MD Paul Griffiths is Professor of Virology at University College, London .
Load more

Recommended publications
  • A Multicenter, Multi-Outbreak, Randomized, Controlled Safety And
    2018 Ebola MCM RCT Protocol Page 1 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease Short Title: 2018 Ebola MCM RCT Protocol Sponsored by: Office of Clinical Research Policy and Regulatory Operations (OCRPRO) National Institute of Allergy and Infectious Diseases 5601 Fishers Lane Bethesda, MD 20892 NIH Protocol Number: 19-I-0003 Protocol IND #: 125530 ClinicalTrials.gov Number: NCT03719586 Date: 4 October 2019 Version: 7.0 CONFIDENTIAL This document is confidential. No part of it may be transmitted, reproduced, published, or used by other persons without prior written authorization from the study sponsor and principal investigator. 2018 Ebola MCM RCT Protocol Page 2 of 92 IND#: 125530 CONFIDENTIAL 4 October 2019, version 7.0 KEY ROLES DRC Principal Investigator: Jean-Jacques Muyembe-Tamfum, MD, PhD Director-General, DRC National Institute for Biomedical Research Professor of Microbiology, Kinshasa University Medical School Kinshasa Gombe Democratic Republic of the Congo Phone: +243 898949289 Email: [email protected] Other International Investigators: see Appendix E Statistical Lead: Lori Dodd, PhD Biostatistics Research Branch, DCR, NIAID 5601 Fishers Lane, Room 4C31 Rockville, MD 20852 Phone: 240-669-5247 Email: [email protected] U.S. Principal Investigator: Richard T. Davey, Jr., MD Clinical Research Section, LIR, NIAID, NIH Building 10, Room 4-1479, Bethesda,
    [Show full text]
  • “Amenalief® Tab. 200Mg” in Japan
    News Release July 3, 2017 Maruho Co., Ltd. Maruho receives manufacturing and marketing approval for Anti-Herpes Virus Agent “Amenalief® Tab. 200mg” in Japan Osaka (Japan), July 3, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces that today it has received manufacturing and marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), for anti-herpes virus agent “Amenalief® Tab. 200mg” (INN: amenamevir) (hereinafter referred to as “the product”) for the treatment of herpes zoster (shingles) in Japan. The product is an anti-herpes virus agent with a novel mechanism of action created by Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka). The product has been observed to inhibit the proliferation of the varicella-zoster virus (hereinafter VZV) by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication. In August 2012, Maruho and Astellas agreed on a license agreement for the development and commercialization of the product in Japan, and Maruho has been progressing its development. Herpes zoster (shingles) is a disease caused by reactivation of the chickenpox VZV in latently-infected nerve ganglia. The main treatment for shingles is anti-herpes virus agents. The product is proven to be effective against VZV when administered once a day after meals. Also, since most of the product is excreted in feces, it is not necessary to adjust the dosage and administration according to creatinine clearance, an indicator of kidney function. Maruho hopes the product will contribute to the expansion of treatment options and improvement in adherence for the treatment of shingles in Japan.
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Rabbit Anti-Marburgvirus (MARV) VLP Pab ELISA Data
    4 Research Court, Suite 300 Rockville, MD 20850 877-411-2041 [email protected] Rabbit anti-Marburgvirus (MARV) VLP pAb ELISA Data: Catalog #: 04-0005 IgG IgG + IgG + Lot #: MMIG201001IBT Dilution MMARV ZEBOV 1:X Antigen Antigen Immunogen: MARV (Musoke strain) Virus-like Particles (VLPs) containing glycoprotein (GP) 1000 3.30 2.66 Nucleoprotein (NP), and viral protein (VP40). 3162 3.07 1.80 10000 2.68 0.89 Description: Protein A purified rabbit polyclonal 31623 1.87 0.37 antibody reactive to MARV VLP raised in New 100000 0.99 0.14 Zealand white rabbits. 316228 0.43 0.05 1000000 0.17 0.02 Supplied: 0.5 mg of antibody is supplied in PBS at a concentration of 5.75 mg/mL. 0.01% Sodium azide has been added. -Antigen is coated on ELISA plates overnight. -Add 200µl blocking buffer then wash wells with Clonality: Polyclonal PBST. -Antiserum is diluted semi-log. Relevance: the filovirus Marburgvirus is a -Incubate antibody for 2 hour. Category A (NIAID) and HHS select agent. -Wash unbound antibodies and add HRP- Recommended Dilutions: conjugated anti-rabbit IgG. -Wash plates and add substrate to develop color for ELISA: Assay-dependent dilution. 20 minutes. WB: Assay-dependent dilution -Read absorbance at 650nm. Amount of color is directly proportional to amount of antibodies. Storage: 2-3 weeks +4oC, -20◦C long term Western Blot Cross Reactivity: Historical data showed some cross-reactivity with Ebola Virus (EBOV) and -Antiserum recognizes Marburg musoke Sudan Virus (SUDV) VLP’s, most likely due to glycoprotein, nucleoprotein, and VP40 antibodies against Baculovirus proteins since the VLP’s were expressed in SF9-Baculovirus system.
    [Show full text]
  • Overview of Antiviral Medications Used in Ophthalmology
    ANTIVIRALS Overview of antiviral medications Jeremy Hoffman Clinical Research used in ophthalmology Fellow: International Centre for Eye Health, As eye health professionals, London School of Hygiene & Tropical we are fortunate to have Medicine, UK. a number of antiviral medications available in our armoury to treat a range of ophthalmic viral infections. This article provides an overview of what antiviral agents are available for these conditions, detailing their regimen SANDIP DAS SANYAM (SAGARMATHA CHOUDHARY EYE HOSPITAL, NEPAL) SANDIP DAS SANYAM(SAGARMATHA and evidence that Aciclovir – either as topical eye ointment or systemic tablets – is still the first-line antiviral in the treatment of many viral eye diseases around the supports their use. world, including here in Nepal. phthalmic viral infections, particularly herpes associated with toxicity, including superficial punctate simplex keratitis, have been at the forefront of keratopathy, chemical conjunctivitis, punctal occlusion Othe development of antiviral medications. and occasional serious hypersensitivity reactions. Idoxuridine was also unable to penetrate the corneal The discovery of the first targeted antiviral agent, epithelium to treat stromal or endothelial keratitis. in common with penicillin (the first antibiotic), owes much to serendipity. In 1959, William Prusoff With the advent of aciclovir in 1982, most herpetic developed idoxuridine (IDU) as a potential systemic ophthalmic infections became treatable, including anti-cancer agent. Idoxuridine those caused by herpes
    [Show full text]
  • Herpes Simplex Virus
    HSV Herpes simplex virus HSV (Herpes simplex virus) can be spread when an infected person is producing and shedding the virus. Herpes simplex can be spread through contact with saliva, such as sharing drinks. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with ascab characteristic of herpetic disease. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. www.MedChemExpress.com 1 HSV Inhibitors (Z)-Capsaicin 1-Docosanol (Zucapsaicin; Civamide; cis-Capsaicin) Cat. No.: HY-B1583 (Behenyl alcohol) Cat. No.: HY-B0222 (Z)-Capsaicin is the cis isomer of capsaicin, acts 1-Docosanol is a saturated fatty alcohol used as an orally active TRPV1 agonist, and is used in traditionally as an emollient, emulsifier, and the research of neuropathic pain. thickener in cosmetics, and nutritional supplement; inhibitor of lipid-enveloped viruses including herpes simplex. Purity: 99.96% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg Size: 500 mg 2-Deoxy-D-glucose 20(R)-Ginsenoside Rh2 (2-DG; 2-Deoxy-D-arabino-hexose; D-Arabino-2-deoxyhexose) Cat. No.: HY-13966 Cat. No.: HY-N1401 2-Deoxy-D-glucose is a glucose analog that acts as 20(R)-Ginsenoside Rh2, a matrix a competitive inhibitor of glucose metabolism, metalloproteinase (MMP) inhibitor, acts as a inhibiting glycolysis via its actions on hexokinase.
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 33, No. 2, 2019 WHO Drug Information Contents Publication News 135 53rd report of the World Health Organization (WHO) Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) Consultation Documents 139 Concept Note: A Framework for Evaluating and Publicly Designating Regulatory Authorities as WHO-Listed Authorities 159 Quality Management System Requirements for National Inspectorates 174 Procedure for the Elaboration, Revision and Omission of Monographs and Other Texts for The International Pharmacopoeia 179 Good Chromatography Practices 194 Good Storage and Distribution Practices for Medical Products ATC/DD Classification 226 ATC/DDD Classification (Temporary) 229 ATC/DDD Classification (Final) International Nonproprietary Names (INN) 233 List No. 121 of Proposed International Nonproprietary Names (INN) for Pharmaceutical Substances Abbreviations and websites CHMP Committee for Medicinal Products for Human Use (EMA) EMA European Medicines Agency (www.ema.europa.eu) EU European Union FDA U.S. Food and Drug Administration (www.fda.gov) Health Canada Federal department responsible for health product regulation in Canada (www.hc-sc.gc.ca) HPRA Health Products Regulatory Authority, Ireland (www.hpra.ie) HSA Health Sciences Authority, Singapore (www.hsa.gov.sg) ICDRA International Conference of Drug Regulatory Authorities ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (www.ich.org) IGDRP International Generic Drug Regulators Programme (https://www.igdrp.com)
    [Show full text]
  • Meeting Report: 26Th International Conference on Antiviral Research Q
    Antiviral Research 100 (2013) 276–285 Contents lists available at ScienceDirect Antiviral Research journal homepage: www.elsevier.com/locate/antiviral Review Meeting report: 26th International Conference on Antiviral Research q R. Anthony Vere Hodge Vere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK article info abstract Article history: The 26th International Conference on Antiviral Research (ICAR) was held in San Francisco, California from Received 2 August 2013 May 11 to 15, 2013. This article summarizes the principal invited lectures at the meeting. The opening Accepted 8 August 2013 symposium on the legacy of the late Antonín Holy´ included presentations on his pioneering work with Available online 21 August 2013 nucleotide analogs, which led to the development of several antiviral drugs including tenofovir. This drug has transformed the treatment of HIV infection and has recently become the first-line therapy for chronic Keywords: hepatitis B. The Gertrude Elion Award lecturer described the anti-HIV activities of the CCR5 inhibitor Human immunodeficiency virus cenicriviroc and the reverse transcriptase inhibitor festinavirÒ, and also reviewed the evaluation of bio- Hepatitis B degradable nanoparticles with adjuvant activity. The William Prusoff Award winner reported on the cre- Hepatitis C Herpesviruses ation of NAOMI, a computer model with 21 enzymes to predict the activity of nucleoside analogs against Antiviral therapy hepatitis C virus (HCV). Other invited lecturers discussed the development of countermeasures against severe dengue and the potential of RNA virus capping and repair enzymes as drug targets. Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investiga- tion of cytomegalovirus resistance to CMX001.
    [Show full text]
  • ATC/DDD Classification
    WHO Drug Information Vol. 32, No. 4, 2018 ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/ DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information. ATC/DDD classification (temporary) The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2018. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology before 1 February 2019. If no objections are received before this date, the new ATC codes and DDDs will be considered final and included in the January 2020 version of the ATC/DDD Index. New ATC 5th level codes ATC level name/INN ATC code acalabrutinib L01XE51 amenamevir J05AX26 amlodipine and celecoxib C08CA51 arginine and lysine V03AF11 atorvastatin and omega-3 fatty acids C10BA08 baloxavir marboxil J05AX25 betrixaban B01AF04 brolucizumab S01LA06 cemiplimab L01XC33 crizanlizumab B06AX01 daclatasvir, asunaprevir and beclabuvir J05AP58 darolutamide L02BB06 elagolix H01CC03 elbasvir J05AP10 entinostat L01XX64 Continued 5 51 ATC/DDD classification WHO Drug Information Vol. 32, No. 4, 2018 New ATC 5th level codes (continued)
    [Show full text]
  • Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development
    YALE JOURNAL OF BIOLOGY AND MEDICINE 93 (2020), pp.381-384. Interview Applications of Traditional Chinese Medicine in Antiviral and Anticancer Drug Development An Interview with Dr. Yung-Chi (Tommy) Cheng, PhD Huaqi Li* MPH Candidate, Yale School of Public Health, Yale University, New Haven, CT You studied chemistry in Taiwan and then went During that period, there was a course offered at into a PhD in biochemical pharmacology at Brown University that invited several pharmacology Brown University. Can you tell us about how professors from other campuses to teach. Among those you first became interested in these fields? was Professor Prusoff who was an expert in antiviral and I was always interested in chemistry and the biologi- cancer research. He synthesized the first antiviral drug cal aspects of chemistry, so my undergraduate major was for the herpes simplex virus (HSV) and I was interested actually a double major in chemistry and biology. So, in that subject, so I decided to do my postdoc with him when I was deciding what to do after my undergraduate at Yale. I came over after receiving my PhD degree and training, I decided to go abroad and applied to universities that was the first time I was exposed to virology. Through in Canada. I was at the University of Guelph for one year. bioassays, we identified a nucleoside analog that was My wife was studying at Brown University, so I reapplied highly selective against HSV-1 and then the question was to Brown, but they didn’t really have a biochemistry de- how could this compound have such selectivity? Because partment, so I needed to decide what specific specialty of before that time, nobody believed that you could come biochemistry I was interested in.
    [Show full text]
  • Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection
    pharmaceuticals Review Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection Isabella Zanella 1,2,* , Daniela Zizioli 1, Francesco Castelli 3 and Eugenia Quiros-Roldan 3 1 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; [email protected] 2 Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy 3 University Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy; [email protected] (F.C.); [email protected] (E.Q.-R.) * Correspondence: [email protected]; Tel.: +39-030-399-6806 Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide with different clinical manifestations. Age and comorbidities may explain severity in critical cases and people living with human immunodeficiency virus (HIV) might be at particularly high risk for severe progression. Nonetheless, current data, although sometimes contradictory, do not confirm higher morbidity, risk of more severe COVID-19 or higher mortality in HIV-infected people with complete access to antiretroviral therapy (ART). A possible protective role of ART has been hypothesized to explain these observations. Anti-viral drugs used to treat HIV infection have been repurposed for COVID-19 treatment; this is also based on previous studies on severe acute respiratory syndrome virus (SARS-CoV) and Middle East respiratory syndrome virus (MERS-CoV). Among Citation: Zanella, I.; Zizioli, D.; them, lopinavir/ritonavir, an inhibitor of viral protease, was extensively used early in the pandemic Castelli, F.; Quiros-Roldan, E.
    [Show full text]
  • Remarks by Jon Soderstrom*
    REMARKS BY JON SODERSTROM* Senator Birch Bayh has made the most significant impact on the U.S. and global economy of any individual who has ever come before and who lives today, full stop. That’s an amazing accomplishment. We have heard about all the legislative feats that he accomplished. We’ve heard about what an amazing legislator, attorney, and public servant he was. But, there are very few human beings who have had the impact on our economy that Senator Bayh had. It’s an amazing accomplishment and something that we should be in awe of. I’m going to give you a few statistics. I’m not going to overwhelm you; I’m going to bring it down to a personal level. I promised Kitty that I wouldn’t cry. Because when I was thinking about this the other day, it’s hard. If you knew Senator Bayh, he wore his emotions on his sleeve, and we have cried together. Here are just a couple statistics that should blow you away. The Bayh- Dole Act1 unleashed the technologies that were being developed in universities in a way that no one probably could have imagined. It was immediate and it was dramatic. The year was 1980. Prior to 1980—and I know because my entire career arc has followed the senator’s accomplishments—I was at graduate school studying the economy and what patents were doing, et cetera. At that time, the federal government, by law, was the owner of all intellectual property created with federal dollars and, as a result, it had created 28,000 patents.2 Less than 5 percent of those patents had ever been licensed or commercialized, compared with 25 percent to 30 percent of the small number of federal patents for which the government had allowed companies to retain title to the invention.3 That is “because the government would only grant nonexclusive licenses to patents it owned,” so * Managing Director, Office of Cooperative Research at Yale University.
    [Show full text]